Human papillomavirus vaccine update

Alisa Ames, Patti Gravitt

Research output: Contribution to journalReview articlepeer-review

Abstract

With the approval of Gardasil® (Merck and Co., Inc., Whitehouse Station, NJ) in June of 2006 and the pending approval of Cervarix® (GlaxoSmithKline, London, UK), two prophylactic human papilomavirus (HPV) vaccines will be available for clinical use. Randomized controlled trials have shown that both vaccines are safe and highly effective in preventing persistent infection and lesions caused by HPV 16 and 18 - the types responsible for 70% of cervical cancers worldwide. Determining an effective vaccination strategy is now the most pressing issue facing clinicians, parents, public health officials, and policy makers. We discuss the appropriate age of vaccination, vaccine acceptance, implementation strategies in low resource settings, and the future of screening.

Original languageEnglish (US)
Pages (from-to)151-158
Number of pages8
JournalCurrent Infectious Disease Reports
Volume9
Issue number2
DOIs
StatePublished - Mar 1 2007

ASJC Scopus subject areas

  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Human papillomavirus vaccine update'. Together they form a unique fingerprint.

Cite this